Full Press Release Details
FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April:
Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website atwww.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visitwww.cartesiantherapeutics.comor follow the Company onLinkedInorX.
Investor Contact
Megan LeDucAssociate Director, Investor Relationsmegan.leduc@cartesiantx.com
Media Contact
David RosenArgot Partnersdavid.rosen@argotpartners.com